Literature DB >> 25770474

Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements.

Daniel Delitto1, Kien Pham2, Adrian C Vlada1, George A Sarosi3, Ryan M Thomas3, Kevin E Behrns1, Chen Liu2, Steven J Hughes1, Shannon M Wallet4, Jose G Trevino5.   

Abstract

Direct implantation of viable surgical specimens provides a representative preclinical platform in pancreatic adenocarcinoma. Patient-derived xenografts consistently demonstrate retained tumor morphology and genetic stability. However, the evolution of the tumor microenvironment over time remains poorly characterized in these models. This work specifically addresses the recruitment and incorporation of murine stromal elements into expanding patient-derived pancreatic adenocarcinoma xenografts, establishing the integration of murine cells into networks of invading cancer cells. In addition, we provide methods and observations in the establishment and maintenance of a patient-derived pancreatic adenocarcinoma xenograft model. A total of 25 histologically confirmed pancreatic adenocarcinoma specimens were implanted subcutaneously into nonobese diabetic severe combined immunodeficiency mice. Patient demographics, staging, pathological analysis, and outcomes were analyzed. After successful engraftment of tumors, histological and immunofluorescence analyses were performed on explanted tumors. Pancreatic adenocarcinoma specimens were successfully engrafted in 15 (60%) of 25 attempts. Successful engraftment does not appear to correlate with clinicopathologic factors or patient survival. Tumor morphology is conserved through multiple passages, and tumors retain metastatic potential. Interestingly, despite morphological similarity between passages, human stromal elements do not appear to expand with invading cancer cells. Rather, desmoplastic murine stroma dominates the xenograft microenvironment after the initial implantation. Recruitment of stromal elements in this manner to support and maintain tumor growth represents a novel avenue for investigation into tumor-stromal interactions.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25770474      PMCID: PMC4419203          DOI: 10.1016/j.ajpath.2015.01.016

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  16 in total

1.  Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.

Authors:  Michael P Kim; Douglas B Evans; Huamin Wang; James L Abbruzzese; Jason B Fleming; Gary E Gallick
Journal:  Nat Protoc       Date:  2009-10-29       Impact factor: 13.491

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  An in vivo platform for translational drug development in pancreatic cancer.

Authors:  Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine Iacobuzio-Donahue; Collins Karikari; Chanjusn Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells Messersmith; James Eshleman; Ralph H Hruban; Anirban Maitra; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

4.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

5.  Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features.

Authors:  Virginie Dangles-Marie; Marc Pocard; Sophie Richon; Louis-Bastien Weiswald; Franck Assayag; Patrick Saulnier; Jean-Gabriel Judde; Jean-Louis Janneau; Nathalie Auger; Pierre Validire; Bernard Dutrillaux; Françoise Praz; Dominique Bellet; Marie-France Poupon
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

Review 6.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

7.  Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

Authors:  Thomas G Roberts; Bernardo H Goulart; Lee Squitieri; Sarah C Stallings; Elkan F Halpern; Bruce A Chabner; G Scott Gazelle; Stan N Finkelstein; Jeffrey W Clark
Journal:  JAMA       Date:  2004-11-03       Impact factor: 56.272

8.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

9.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Authors:  J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

10.  Transcriptional dissection of pancreatic tumors engrafted in mice.

Authors:  Raquel Martinez-Garcia; David Juan; Antonio Rausell; Manuel Muñoz; Natalia Baños; Camino Menéndez; Pedro P Lopez-Casas; Daniel Rico; Alfonso Valencia; Manuel Hidalgo
Journal:  Genome Med       Date:  2014-04-16       Impact factor: 11.117

View more
  50 in total

1.  Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.

Authors:  Daniel Delitto; Chelsey Perez; Song Han; David H Gonzalo; Kien Pham; Andrea E Knowlton; Christina L Graves; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Chen Liu; Thomas J George; Jose G Trevino; Shannon M Wallet; Steven J Hughes
Journal:  Cancer Immunol Immunother       Date:  2015-09-30       Impact factor: 6.968

2.  Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.

Authors:  Aslamuzzaman Kazi; Shengyan Xiang; Hua Yang; Liwei Chen; Perry Kennedy; Muhammad Ayaz; Steven Fletcher; Christopher Cummings; Harshani R Lawrence; Francisca Beato; Ya'an Kang; Michael P Kim; Andrea Delitto; Patrick W Underwood; Jason B Fleming; Jose G Trevino; Andrew D Hamilton; Said M Sebti
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

3.  Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture.

Authors:  Kien Pham; Daniel Delitto; Andrea E Knowlton; Emily R Hartlage; Ricky Madhavan; David H Gonzalo; Ryan M Thomas; Kevin E Behrns; Thomas J George; Steven J Hughes; Shannon M Wallet; Chen Liu; Jose G Trevino
Journal:  Am J Pathol       Date:  2016-04-18       Impact factor: 4.307

Review 4.  Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models.

Authors:  Sally E Henderson; Neil Makhijani; Thomas A Mace
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

Review 5.  Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Authors:  Annette T Byrne; Denis G Alférez; Frédéric Amant; Daniela Annibali; Joaquín Arribas; Andrew V Biankin; Alejandra Bruna; Eva Budinská; Carlos Caldas; David K Chang; Robert B Clarke; Hans Clevers; George Coukos; Virginie Dangles-Marie; S Gail Eckhardt; Eva Gonzalez-Suarez; Els Hermans; Manuel Hidalgo; Monika A Jarzabek; Steven de Jong; Jos Jonkers; Kristel Kemper; Luisa Lanfrancone; Gunhild Mari Mælandsmo; Elisabetta Marangoni; Jean-Christophe Marine; Enzo Medico; Jens Henrik Norum; Héctor G Palmer; Daniel S Peeper; Pier Giuseppe Pelicci; Alejandro Piris-Gimenez; Sergio Roman-Roman; Oscar M Rueda; Joan Seoane; Violeta Serra; Laura Soucek; Dominique Vanhecke; Alberto Villanueva; Emilie Vinolo; Andrea Bertotti; Livio Trusolino
Journal:  Nat Rev Cancer       Date:  2017-01-20       Impact factor: 60.716

6.  Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens.

Authors:  Matthew C Hernandez; John R Bergquist; Jennifer L Leiting; Tommy Ivanics; Lin Yang; Rory L Smoot; David M Nagorney; Mark J Truty
Journal:  J Gastrointest Surg       Date:  2019-02-12       Impact factor: 3.452

7.  Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment.

Authors:  Daniel Delitto; Andrea E Delitto; Bayli B DiVita; Kien Pham; Song Han; Emily R Hartlage; Brittney N Newby; Michael H Gerber; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Thomas J George; Todd M Brusko; Clayton E Mathews; Chen Liu; Jose G Trevino; Steven J Hughes; Shannon M Wallet
Journal:  Cancer Res       Date:  2016-11-18       Impact factor: 12.701

8.  Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model.

Authors:  Weijing Cai; Ranjala Ratnayake; Michael H Gerber; Qi-Yin Chen; Yichao Yu; Hartmut Derendorf; Jose G Trevino; Hendrik Luesch
Journal:  Invest New Drugs       Date:  2018-08-03       Impact factor: 3.850

9.  Modeling pancreatic cancer with organoids.

Authors:  Lindsey A Baker; Hervé Tiriac; Hans Clevers; David A Tuveson
Journal:  Trends Cancer       Date:  2016-04

Review 10.  Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.

Authors:  Elvira Pelosi; Germana Castelli; Ugo Testa
Journal:  Biomedicines       Date:  2017-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.